The flozins are generally too expensive in the USA for most to consider. India provides a cost-effective quality solution.
1 Like
Nick1
#1527
Yeah, I looked it up at Mark Cuban’s Costplus (which is most economical of all pharmacies) and its over 10 bucks a pill
1 Like
India is around $60 for a month’s supply, or about $2 per pill.
1 Like
Aren’t these going generic soon?
They are starting to… and there seems to be at least one that may be relatively inexpensive:
The SGLT2i bexagliflozin was approved in January 2023 as adjunctive therapy to lower blood glucose in patients with type 2 diabetes. Patients with an estimated glomerular filtration rate less than 30 are excluded on the label (4). Bexagliflozin (brand name Brenzavvy) was not expected to have much success as a late entrant into the field, especially since established SGLT2i, including dapagliflozin (Farxiga), canagliflozin (Invokana), and empagliflozin (Jardiance), have additional cardiovascular and kidney-labeled indications. However, in a novel marketing approach, bexagliflozin is available exclusively through Cost Plus Drugs at a cash price of approximately $50 per month (5). There are no required patient assistance programs or other qualifying steps to access the medication (Table 1). Prescribing physicians should exercise their best clinical judgment to determine if the evidence for a class effect of the SGLT2i is enough to warrant off-label use of bexagliflozin to provide benefit among patients with cardiovascular and kidney diseases.
AstraZeneca’s Farxiga (dapagliflozin) does not go off patent until 2025, and in 2021, AstraZeneca successfully defended its patent against a challenge from a manufacturer of generic medications (6). However, generic dapagliflozin is now available in the United States. In a marketing strategy familiar to Costco shoppers, who purchase brand name products sold under the Kirkland label at a significant discount, AstraZeneca has licensed Prasco to sell dapagliflozin as an authorized generic. The medication is manufactured in the same facility as the branded product and is identical other than the packaging (7). There is the potential for savings to be passed on to the consumer, although the savings may also be captured by pharmacy benefit managers and the pharmacies.
Source: Newer Options for SGLT2 Inhibitors in the United States in: Kidney News Volume 16 Issue 4 (2024)
Relacionado:
FDA Moves Generic Dapagliflozin a Step Closer to US Sales
Mitchel L. Zoler, PhD
February 23, 2022
However, the Zydus formulations of dapagliflozin will likely not soon appear on the US market because in October 2021 the company failed in its bid in US District Court to invalidate the patent that AstraZeneca holds on dapagliflozin through 2025 based on a claim of “obviousness.” The court dismissed the Zydus claims and upheld the validity of the patent.
https://www.medscape.com/viewarticle/969050
https://www.goodrx.com/classes/sglt2-inhibitors/sglt2-inhibitors-list
5 Likes
That’s very interesting.
Looks like it’s as good as dapagliflozin:
Efficacy and safety of bexagliflozin compared with dapagliflozin as an adjunct to metformin in Chinese patients with type 2 diabetes mellitus: A 24-week, randomized, double-blind, active-controlled, phase 3 trial
For the primary endpoint of change in HbA1c from baseline to week 24, the main objective to demon-
strate that bexagliflozin was noninferior to dapagliflozin
was achieved. The similar reductions in HbA1c observed
with bexagliflozin and dapagliflozin suggest that both
SGLT2 inhibitors are effective in glycemic control.
2 Likes
LOL, I did the same thing - immediately started scouring PubMed for info about bexagliflozin. I did find that it works in cats, which is always nice to know (for us, cat owners) as diabetes is very prevalent among cats. So it’s comforting to know that as you’re popping your SGLT2i, you might give some to your cat - the little guys are on the same journey as we are: rapamycin, sglt2i etc. I posted the relevant study in a cat thread although a bit OT as the thread is about rapamycin.
3 Likes
cl-user
#1534
I’ve also seen the one on humans and cat. I found it was rather funny.
1 Like
